Paper Details

  1. Home
  2. Paper Details

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis.

Author: BroströmO, DanielssonA, FlorénC, HultcrantzR, JärnerotG, KilanderA, LöfbergR, LööfL, NilssonA, StrömM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs may be more effective than 5-ASA alone in maintaining remission in ulcerative colitis (UC) patients. In a study of 199 patients, allopurinol group had a higher remission rate at 6 months (77% vs 59%). However, this difference was not observed at 12 months.
Paper Details　
Original Abstract of the Article :
BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC). METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2000.00821.x

データ提供：米国国立医学図書館（NLM）

Allopurinol: A New Approach for Ulcerative Colitis Maintenance

Ulcerative colitis (UC), a chronic inflammatory bowel disease, is like a persistent sandstorm in the desert of human health. This study, an exploration into the realm of alternative treatments, investigated the potential benefits of combining allopurinol with 5-aminosalicylic acid (5-ASA) based drugs for maintaining remission in UC patients. The researchers, like skilled healers, set out to discover whether this new combination could offer a more effective and durable treatment for this challenging disease.

A Promising Oasis in the Desert

The study's findings, like a shimmering oasis in the desert, suggest that adding allopurinol to 5-ASA based maintenance treatment could offer a more effective approach for maintaining remission in UC patients, particularly in the early stages of treatment. The researchers' observations, like footprints leading to a hidden spring, indicate that this combination might be a valuable option for patients seeking a more effective and durable treatment for UC. This research, like a caravan carrying precious water, offers a potential solution for those seeking a more comfortable and manageable life with UC.

Navigating the Desert of UC

The study's findings, like a guiding star in the desert, illuminate a new path for treating UC. This combination therapy, like a well-stocked oasis, offers a potential solution for patients facing the challenges of this debilitating disease. This research, like a camel caravan traversing the desert, encourages further exploration of alternative therapies, seeking better outcomes for patients battling this relentless condition.

Dr.Camel's Conclusion

Ulcerative colitis (UC), a chronic inflammatory bowel disease, is like a relentless sandstorm in the desert of human health. This study, like a caravan carrying hope, reveals the potential benefits of combining allopurinol with 5-ASA based drugs for maintaining remission in UC patients. The researchers' findings suggest that this combination could offer a more effective and durable treatment, providing a more comfortable and manageable life for those affected by this disease.

Date :
  1. Date Completed 2000-10-19
  2. Date Revised 2019-08-31
Further Info :

Pubmed ID

10971232

DOI: Digital Object Identifier

10.1046/j.1365-2036.2000.00821.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.